Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
JAZZ Stock Chart & Stats
$165.00
-$1.17(-0.95%)
At close: 4:00 PM EST
$165.00
-$1.17(-0.95%)
Day’s Range― - ―
52-Week Range$95.49 - $182.99
Previous CloseN/A
Volume75.28K
Average Volume (3M)963.67K
Market Cap
$10.06B
Enterprise Value$14.22B
Total Cash (Recent Filing)$2.05B
Total Debt (Recent Filing)$5.43B
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Mar 03, 2026EPS Estimate
6.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.13
Shares Outstanding60,765,118
10 Day Avg. Volume727,350
30 Day Avg. Volume963,666
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)1.86
Price to Sales (P/S)1.87
P/FCF Ratio5.65
Enterprise Value/Market Cap1.41
Enterprise Value/Revenue3.42
Enterprise Value/Gross Profit4.00
Enterprise Value/Ebitda55.21
Forecast
1Y Price Target
$222.50Price Target Upside34.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 3 HERIZON-GEA-01 data showed Ziihera combinations delivered statistically significant survival and progression benefits versus the current standard, positioning the drug as a potential new first-line HER2 backbone in gastric cancer.
Commercial PotentialAnalyst valuation upgrades reflect expectations that premium pricing and a large addressable HER2 market could generate substantial sales if Ziihera achieves broad market uptake.
Regulatory OutlookManagement plans to pursue regulatory approval and rapid inclusion in clinical guidelines for a broad label that does not require a biomarker test, supporting a clearer path to commercialization.
Bears Say
Execution RiskPlanned additional clinical analyses create execution risk because future results could change current expectations for treatment benefit and reduce projected market uptake.
Portfolio Concentration And CompetitionReliance on oncology upside is tempered by a lack of other sizable growth drivers and expected downward pricing pressure from generic Xyrem in the neuroscience franchise, which could limit overall upside.
Safety And TolerabilityHigher diarrhea rates with zanidatamab compared with control raise tolerability concerns that could hinder adoption or require additional management strategies.
Jazz Pharmaceuticals News
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $95.49 and its highest was $182.99 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $10.06B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Mar 03, 2026 which is in 20 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Nov 05, 2025. The company reported $8.13 earnings per share for the quarter, beating the consensus estimate of $5.946 by $2.184.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 6.53.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 60,765,118 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $8.13 in its last earnings report, beating expectations of $5.946. Following the earnings report the stock price went down -2.31%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in JAZZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jazz Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$222.50 (34.85% Upside)
$222.50 (34.85% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 88%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 360.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.16%
12-Months-Change
Fundamentals
Return on Equity
-9.06%
Trailing 12-Months
Asset Growth
-7.34%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
JAZZ Company Deck
JAZZ Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Jazz Pharmaceuticals had a strong third quarter with record revenue, multiple FDA approvals, and robust growth in key products. The company also addressed legal challenges with settlements and continued to advance its pipeline. However, concerns about future competition from generics and a decline in Zepzelca sales present challenges.View all JAZZ earnings summariesJAZZ Stock 12 Month Forecast
Average Price Target
$222.50
▲(34.85% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Bio-Techne
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
3.57% Insiders
30.06% Mutual Funds
0.13% Other Institutional Investors
41.47% Public Companies and
Individual Investors